October is National Healthy Lung Month. Our CAN-2409 NSCLC program shows promise: 21.5 months median survival vs 9.8-11.8 months with standard treatment in patients with progressive disease. Lung cancer claims 1.8M+ lives annually. Every breakthrough matters. #HealthyLungMonth

Congratulations to Candel’s Chief Regulatory Officer Susan Stewart, on receiving the regulatory profession's highest honor - the RAPS Founder’s Award! https://t.co/Ra3rSbP7mu $CADL #RAPSAwards #RegulatoryAffairs

Dr. John E. Sylvester from Atlantic Urology Clinics. presented CAN-2409 phase 3 data in an oral presentation at Future Directions in Urology Symposium. Thank you to the urology community for the engaging discussions and valuable feedback. $CADL #UrologyCongress

We’ll be at #SITC2025! Presenting posters on our enLIGHTEN platform and CAN-2409 in NSCLC, plus our CEO @paulpetertak will speak on our phase 3 prostate cancer data. See the curtain raiser: https://t.co/9Mb8TkDyMH #Immunotherapy #ProstateCancer #NSCLC

Our prostate cancer data from the phase 3 CAN-2409 trial will be presented in an oral presentation at the Future Directions in Urology Symposium by Dr. John E. Sylvester from Atlantic Urology Clinics. https://t.co/xglePNaEpq #ProstateCancer #Urology $CADL

We’re presenting our phase 3 CAN-2409 localized prostate cancer trial at #ASTRO2025, with a subanalysis focused on type of radiation therapy used in the trial. https://t.co/k1c7Tq7UlJ #ProstateCancer #ClinicalData #RadiationOncology

On #WorldCancerResearchDay, we spotlight our enLIGHTEN Discovery Platform - that analyzes tumor microenvironments to design targeted viral immunotherapies. Research advances like these build on the dedication of investigators, clinicians, and patients in clinical trials.

Exciting milestone ahead with CAN-2409 targeting a late 2026 U.S. filing after phase 3 prostate cancer success. With strong cash position through early 2027, our viral immunotherapy continues showing promise across multiple cancer types. https://t.co/0ebXdIpufT $CADL

Attending #ASTRO25? Dr. Gejerman will present our phase 3 prostate cancer study. The data represents potential progress for ~65k men diagnosed annually with intermediate-to-high-risk localized prostate cancer who undergo radiotherapy with curative intent. https://t.co/OpRlzLEUNk

Our CEO @PaulPeterTak and VP of IR & BD Ted Jenkins are attending BioCentury Grand Rounds. We’ll discuss our enLIGHTEN™ Discovery Platform and how it systematically identifies tumor microenvironment characteristics that correlate with clinical outcomes. https://t.co/qxdiAD5Dbu

It's #ProstateCancer Awareness Month. At Candel, we’re advancing beyond traditional treatments with our viral immunotherapy approach. CAN-2409 is designed to train the immune system to recognize and attack cancer cells, potentially providing lasting protection against recurrence.

We’re participating in the H.C. Wainwright Annual Global Investment Conference. With $100.7 million in cash as of June 30, 2025, we’re well-positioned to fund operations into Q1 2027 and execute on key value-creating milestones. https://t.co/9v622DYrKZ $CADL #HCWainwright

Dr. Charu Aggarwal from @PennMedicine is presenting CAN-2409 NSCLC data at @IASLC 2025. Candel’s phase 2a trial in ICI-resistant patients showed 21.5 months median OS vs 9.8-11.8 months with standard chemotherapy. https://t.co/JmzEs6R8va #WCLC25 #LungCancer #ClinicalData

We are presenting at Cantor Global Healthcare Conference in NYC. Our CEO @PaulPeterTak will discuss CAN-2409’s 30% improvement in disease-free survival for localized prostate cancer and our clinical pipeline. https://t.co/9v622DYrKZ $CADL #CantorHealthcare #CancerResearch

We’re attending Citi’s 2025 BioPharma Back to School Conference in Boston. Our CEO @PaulPeterTak will present our corporate strategy across multiple solid tumor indications. https://t.co/9v622DYrKZ $CADL #CitiBioPharma #ProstateCancer

Excited to announce Carl H. June, MD, CAR-T cell immunotherapy pioneer, has joined Candel’s Research Advisory Board! Dr. June’s expertise in immunotherapy for cancer will be invaluable as we advance our viral immunotherapy programs. https://t.co/itEfBCedXI $CADL

Thank you @medpagetoday for covering our CAN-2409 phase 3 prostate cancer data. The article highlights CAN-2409's ‘potential paradigm shift’ for men with intermediate-to-high-risk prostate cancer. https://t.co/P9HS4atFLo

Today we announced presentations at 3 upcoming investor conferences in September! Join us in Boston & NYC as we discuss our viral immunotherapy pipeline, including CAN-2409’s phase 3 success in prostate cancer. Details: https://t.co/9v622DYrKZ $CADL

Today we announced our financial results and provided corporate updates on our development programs. Progress on our BLA preparations for CAN-2409 in prostate cancer and updates on our financial position as we execute on key value-creating milestones. https://t.co/DuMWahr9uR

Our CEO @paulpetertak will present at the 44th Annual Canaccord Genuity Growth Conference. Be sure to connect with us if you're attending the conference. https://t.co/eZkgnLI0jl $CADL